Seeking Alpha
28 Jul 2026, 06:38 UTC · 2h ago
Genmab's H1 Preview: Darzalex Beats The Sales Outlook
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
28 Jul 2026, 06:38 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
DARZALEX H1 sales reached $8.17B, putting Genmab on track to exceed the high end of its $16.0B–$16.4B full-year guidance. — Direct revenue outperformance of a flagship product typically drives immediate positive price action for the equity.
+0.60A buy rating was issued for Genmab with a 12-month price target of $36, implying 25% upside. — Analyst upgrades and significant price target premiums provide a positive catalyst for investor sentiment.
+0.40Which stocks this story touches
The company has a buy rating with significant upside potential and strong sales performance for DARZALEX exceeding guidance.
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
2h ago
